Alira Health announces role as Strategic Adviser to LEO Pharma.

Alira Health is proud to announce its role as Strategic Adviser to LEO Pharma in the sale of a portfolio of four pharmaceutical products in the dermatology and nephrology space to Cheplapharm.

LEO Pharma announced the sale of One-Alpha®, Locoid®, Pimafucin® and Zineryt® on August 31, 2020 for a price which values the product portfolio at EUR 300 million. The agreement represents a milestone in the company’s strategic focus on new innovative solutions for medical dermatology.

LEO Pharma is a global leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908, the company is dedicated to advancing the science of dermatology and setting new standards of care for people with skin conditions.

For more information, please contact Joris Pezzini.

Learn more about Alira Health’s Transaction Advisory Practice here.